glp 1 drugs for weight loss insurance coverage Why payers are hesitant to cover GLP-1 Employers Grapple with Claims Costs

J Orthop Res 23(2):281286 Gosens T, Den Oudsten BL, Fievez E, vantSpijker P, Fievez A (2012) Pain and activity levels before and after platelet-rich plasma injection treatment of patellar tendinopathy: a prospective cohort study and the influence of previous treatments

The mechanism of action of these drugs is mainly achieved through antioxidant effects and the clearance of free radicals to achieve therapeutic effects

They contain Melanotan II which is banned in medical products in the UK Labelling is poor and there has been no testing to ensure they are safe for the consumer, short-term or longer-term Theyve been known to cause very serious side-effects for some users

In that case, how do they help